Literature DB >> 29084742

Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.

Julie Autmizguine1, Chiara Melloni2, Christoph P Hornik2, Samantha Dallefeld2, Barrie Harper2, Ram Yogev3, Janice E Sullivan4, Andrew M Atz5, Amira Al-Uzri6, Susan Mendley7, Brenda Poindexter8, Jeff Mitchell9, Andrew Lewandowski9, Paula Delmore10, Michael Cohen-Wolkowiez2, Daniel Gonzalez11.   

Abstract

Trimethoprim (TMP)-sulfamethoxazole (SMX) is used to treat various types of infections, including community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) and Pneumocystis jirovecii infections in children. Pharmacokinetic (PK) data for infants and children are limited, and the optimal dosing is not known. We performed a multicenter, prospective PK study of TMP-SMX in infants and children. Separate population PK models were developed for TMP and SMX administered by the enteral route using nonlinear mixed-effects modeling. Optimal dosing was determined on the basis of the matching adult TMP exposure and attainment of the surrogate pharmacodynamic (PD) target for efficacy, a free TMP concentration above the MIC over 50% of the dosing interval. Data for a total of 153 subjects (240 samples for PK analysis) with a median postnatal age of 8 years (range, 0.1 to 20 years) contributed to the analysis for both drugs. A one-compartment model with first-order absorption and elimination characterized the TMP and SMX PK data well. Weight was included in the base model for clearance (CL/F) and volume of distribution (V/F). Both TMP and SMX CL/F increased with age. In addition, TMP and SMX CL/F were inversely related to the serum creatinine and albumin concentrations, respectively. The exposure achieved in children after oral administration of TMP-SMX at 8/40 mg/kg of body weight/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 320/1,600 mg/day divided into administration every 12 h and achieved the PD target for bacteria with an MIC of 0.5 mg/liter in >90% of infants and children. The exposure achieved in children after oral administration of TMP-SMX at 12/60 and 15/75 mg/kg/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 640/3,200 mg/day divided into administration every 12 h in subjects 6 to <21 years and 0 to <6 years of age, respectively, and was optimal for bacteria with an MIC of up to 1 mg/liter.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  children; infants; methicillin-resistant Staphylococcus aureus; pharmacokinetics; sulfamethoxazole; trimethoprim

Mesh:

Substances:

Year:  2017        PMID: 29084742      PMCID: PMC5740321          DOI: 10.1128/AAC.01813-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  44 in total

Review 1.  Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

2.  Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

Authors:  Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Comput Methods Programs Biomed       Date:  2010-06-02       Impact factor: 5.428

3.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

4.  In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.

Authors:  Rodrigo E Mendes; Gary J Moet; Mike J Janechek; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

5.  Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.

Authors:  Hideaki Kagaya; Masatomo Miura; Takenori Niioka; Mitsuru Saito; Kazuyuki Numakura; Tomonori Habuchi; Shigeru Satoh
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

6.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

7.  A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods.

Authors:  R W Jelliffe; P Gomis; B Tahani; J Ruskin; F R Sattler
Journal:  Ther Drug Monit       Date:  1997-08       Impact factor: 3.681

8.  Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS.

Authors:  M E Klepser; Z Zhu; D P Nicolau; M A Banevicius; P P Belliveau; J W Ross; L Broisman; R Quintiliani; C H Nightingale
Journal:  Pharmacotherapy       Date:  1996 Jul-Aug       Impact factor: 4.705

9.  Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers.

Authors:  R C Stevens; S C Laizure; P L Sanders; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Authors:  Ron J Keizer; Robert S Jansen; Hilde Rosing; Bas Thijssen; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Pharmacol Res Perspect       Date:  2015-03-25
View more
  7 in total

1.  Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children.

Authors:  Elizabeth J Thompson; Huali Wu; Anil Maharaj; Andrea N Edginton; Stephen J Balevic; Marjan Cobbaert; Anthony P Cunningham; Christoph P Hornik; Michael Cohen-Wolkowiez
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

2.  Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling.

Authors:  Jacqueline G Gerhart; Fernando O Carreño; Andrea N Edginton; Jaydeep Sinha; Eliana M Perrin; Karan R Kumar; Aruna Rikhi; Christoph P Hornik; Vincent Harris; Samit Ganguly; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  Clin Pharmacokinet       Date:  2021-10-07       Impact factor: 5.577

3.  External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole.

Authors:  Yi Shuan S Wu; Michael Cohen-Wolkowiez; Christoph P Hornik; Jacqueline G Gerhart; Julie Autmizguine; Marjan Cobbaert; Daniel Gonzalez
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.938

4.  Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ß-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis.

Authors:  Chitra Punjabi; Vivian Tien; Lina Meng; Stan Deresinski; Marisa Holubar
Journal:  Open Forum Infect Dis       Date:  2019-08-14       Impact factor: 3.835

5.  Acute and long-term effects of antibiotics commonly used in laboratory animal medicine on the fecal microbiota.

Authors:  Scott W Korte; Rebecca A Dorfmeyer; Craig L Franklin; Aaron C Ericsson
Journal:  Vet Res       Date:  2020-09-14       Impact factor: 3.683

6.  First international quality control programme for laboratories measuring antimicrobial drugs to support dose individualization in critically ill patients.

Authors:  E Wallenburg; R J Brüggemann; K Asouit; M Teulen; A F J de Haan; E J F Franssen; R E Aarnoutse
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790

Review 7.  Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review.

Authors:  Abdul Haseeb; Mohammed A S Abourehab; Wesam Abdulghani Almalki; Abdulrahman Mohammed Almontashri; Sultan Ahmed Bajawi; Anas Mohammed Aljoaid; Bahni Mohammed Alsahabi; Manal Algethamy; Abdullmoin AlQarni; Muhammad Shahid Iqbal; Alaa Mutlaq; Saleh Alghamdi; Mahmoud E Elrggal; Zikria Saleem; Rozan Mohammad Radwan; Ahmad Jamal Mahrous; Hani Saleh Faidah
Journal:  Int J Environ Res Public Health       Date:  2022-02-28       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.